Serum miRNA signature in Moyamoya disease.

Moyamoya disease (MMD) is a cerebrovascular disease characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches. However, the etiology of this rare disease remains unknown. Serum microRNA (miRNA) profiles have been screened to identify novel biomar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dongwei Dai, Qiong Lu, Qinghai Huang, Pengfei Yang, Bo Hong, Yi Xu, Wenyuan Zhao, Jianmin Liu, Qiang Li
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c276d9449aef4b19822eeabcbae47bcf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c276d9449aef4b19822eeabcbae47bcf
record_format	dspace
spelling	oai:doaj.org-article:c276d9449aef4b19822eeabcbae47bcf2021-11-25T06:05:53ZSerum miRNA signature in Moyamoya disease.1932-620310.1371/journal.pone.0102382https://doaj.org/article/c276d9449aef4b19822eeabcbae47bcf2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25093848/?tool=EBIhttps://doaj.org/toc/1932-6203Moyamoya disease (MMD) is a cerebrovascular disease characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches. However, the etiology of this rare disease remains unknown. Serum microRNA (miRNA) profiles have been screened to identify novel biomarkers of prognostic values. Here, we identified serum miRNAs that might play an important role in the pathogenesis of MMD. A genome-wide miRNA array analysis of two pooled serum samples from patients with MMD and controls revealed 94 differentially expressed serum miRNAs, including 50 upregulated and 44 downregulated miRNAs. In an independent MMD cohort, real-time PCR confirmed that miR-106b, miR-130a and miR-126 were significantly upregulated while miR-125a-3p was significantly downregulated in serum. GO analysis showed that the differentially expressed serum miRNAs were enriched in metabolic processes, transcription and signal transduction. Pathway analysis showed that the most enriched pathway was mTOR signaling pathway with 16 potential, functional targets. Finally, we found that 16 and 13 aberrant serum miRNAs coordinately inhibited RNF213 and BRCC3 protein expression at the posttranscriptional level, respectively, resulting in defective angiogenesis and MMD pathogenesis. To our knowledge, this is the first study to identify a serum miRNA signature in MMD. Modulation of the mechanism underlying the role of serum miRNAs in MMD is a potential therapeutic strategy and warrants further investigations.Dongwei DaiQiong LuQinghai HuangPengfei YangBo HongYi XuWenyuan ZhaoJianmin LiuQiang LiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 8, p e102382 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Dongwei Dai Qiong Lu Qinghai Huang Pengfei Yang Bo Hong Yi Xu Wenyuan Zhao Jianmin Liu Qiang Li Serum miRNA signature in Moyamoya disease.
description	Moyamoya disease (MMD) is a cerebrovascular disease characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches. However, the etiology of this rare disease remains unknown. Serum microRNA (miRNA) profiles have been screened to identify novel biomarkers of prognostic values. Here, we identified serum miRNAs that might play an important role in the pathogenesis of MMD. A genome-wide miRNA array analysis of two pooled serum samples from patients with MMD and controls revealed 94 differentially expressed serum miRNAs, including 50 upregulated and 44 downregulated miRNAs. In an independent MMD cohort, real-time PCR confirmed that miR-106b, miR-130a and miR-126 were significantly upregulated while miR-125a-3p was significantly downregulated in serum. GO analysis showed that the differentially expressed serum miRNAs were enriched in metabolic processes, transcription and signal transduction. Pathway analysis showed that the most enriched pathway was mTOR signaling pathway with 16 potential, functional targets. Finally, we found that 16 and 13 aberrant serum miRNAs coordinately inhibited RNF213 and BRCC3 protein expression at the posttranscriptional level, respectively, resulting in defective angiogenesis and MMD pathogenesis. To our knowledge, this is the first study to identify a serum miRNA signature in MMD. Modulation of the mechanism underlying the role of serum miRNAs in MMD is a potential therapeutic strategy and warrants further investigations.
format	article
author	Dongwei Dai Qiong Lu Qinghai Huang Pengfei Yang Bo Hong Yi Xu Wenyuan Zhao Jianmin Liu Qiang Li
author_facet	Dongwei Dai Qiong Lu Qinghai Huang Pengfei Yang Bo Hong Yi Xu Wenyuan Zhao Jianmin Liu Qiang Li
author_sort	Dongwei Dai
title	Serum miRNA signature in Moyamoya disease.
title_short	Serum miRNA signature in Moyamoya disease.
title_full	Serum miRNA signature in Moyamoya disease.
title_fullStr	Serum miRNA signature in Moyamoya disease.
title_full_unstemmed	Serum miRNA signature in Moyamoya disease.
title_sort	serum mirna signature in moyamoya disease.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/c276d9449aef4b19822eeabcbae47bcf
work_keys_str_mv	AT dongweidai serummirnasignatureinmoyamoyadisease AT qionglu serummirnasignatureinmoyamoyadisease AT qinghaihuang serummirnasignatureinmoyamoyadisease AT pengfeiyang serummirnasignatureinmoyamoyadisease AT bohong serummirnasignatureinmoyamoyadisease AT yixu serummirnasignatureinmoyamoyadisease AT wenyuanzhao serummirnasignatureinmoyamoyadisease AT jianminliu serummirnasignatureinmoyamoyadisease AT qiangli serummirnasignatureinmoyamoyadisease
_version_	1718414188646236160

Serum miRNA signature in Moyamoya disease.

Ejemplares similares